Phio Pharmaceuticals Announces Strategic Initiative and Leadership Changes

An update from Phio Pharmaceuticals ( (PHIO) ) is now available.

On June 6, 2025, Phio Pharmaceuticals announced a strategic initiative to increase awareness of its INTASYL siRNA portfolio, following positive interim results from a Phase 1b clinical trial. Concurrently, Lisa Carson was appointed as VP, Finance and Administration, and Robert Infarinato transitioned to VP, Strategic Development, highlighting the company’s focus on expanding the potential applications of its INTASYL technology.

The most recent analyst rating on (PHIO) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.

Spark’s Take on PHIO Stock

According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.

Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.

To see Spark’s full report on PHIO stock, click here.

More about Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology for immuno-oncology. The company’s lead clinical program involves the INTASYL compound PH-762, designed to silence the PD-1 gene implicated in various forms of skin cancer, with ongoing Phase 1b trials evaluating its efficacy as a potential non-surgical treatment for skin cancers.

Average Trading Volume: 3,270,729

Technical Sentiment Signal: Sell

Current Market Cap: $11.85M

See more data about PHIO stock on TipRanks’ Stock Analysis page.